• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

391例日本原发性硬化性胆管炎患者的预后及预后因素

Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis.

作者信息

Tanaka Atsushi, Takamori Yoriyuki, Toda Gotaro, Ohnishi Saburo, Takikawa Hajime

机构信息

Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

出版信息

Liver Int. 2008 Aug;28(7):983-9. doi: 10.1111/j.1478-3231.2008.01726.x. Epub 2008 Apr 7.

DOI:10.1111/j.1478-3231.2008.01726.x
PMID:18397233
Abstract

OBJECTIVES

We performed a national survey in 2003, and demonstrated characteristic features of primary sclerosing cholangitis (PSC) patients in Japan. In this study, we aimed to clarify the outcome and prognostic factors of Japanese PSC patients.

METHODS

Questionnaires were sent to gastroenterologists in Japan, and 391 patients with PSC were registered and enrolled in the current study. The median follow-up was 5.3 years (range 0.1-20.8 years). The cumulative incidence for survival was analysed using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox-proportional hazards regression model for determining prognostic variables.

RESULTS

The estimated median survival of all patients was 13.1 years, with a 5-year survival rate of 74.5%. Thirty-eight patients (9.7%) who underwent liver transplantation (LT) had a 5-year survival rate of 92.0%. Both univariate and multivariate analysis demonstrated that younger age [below 49 years old; odds ratio (OR)=1.76, 1.12-2.76, P=0.0136] and lower total bilirubin (below 3.0 mg/dl; OR=2.50, 1.60-3.89, P<or=0.0001) were independent prognostic factors for LT-free survival of PSC patients in Japan. Cholangiocarcinoma (CCA) was found in 14 (3.6%) patients, and only two out of 125 PSC patients exhibited a history of inflammatory bowel diseases.

CONCLUSIONS

Although several characteristic features existed, the outcome as well as prognostic factors of Japanese PSC patients appeared to be similar to those from the United States and European countries. In contrast, the incidence of CCA in PSC appeared to be lower in Japan.

摘要

目的

我们在2003年进行了一项全国性调查,展示了日本原发性硬化性胆管炎(PSC)患者的特征。在本研究中,我们旨在阐明日本PSC患者的预后及预后因素。

方法

向日本的胃肠病学家发送问卷,391例PSC患者被登记并纳入本研究。中位随访时间为5.3年(范围0.1 - 20.8年)。使用Kaplan-Meier方法分析生存累积发生率。使用Cox比例风险回归模型进行单因素和多因素分析以确定预后变量。

结果

所有患者的估计中位生存期为13.1年,5年生存率为74.5%。38例(9.7%)接受肝移植(LT)的患者5年生存率为92.0%。单因素和多因素分析均表明,年龄较小[49岁以下;比值比(OR)=1.76,1.12 - 2.76,P = 0.0136]和总胆红素较低(3.0mg/dl以下;OR = 2.50,1.60 - 3.89,P≤0.0001)是日本PSC患者无LT生存的独立预后因素。14例(3.6%)患者发现胆管癌(CCA),125例PSC患者中只有2例有炎症性肠病病史。

结论

尽管存在一些特征,但日本PSC患者的预后及预后因素似乎与美国和欧洲国家的患者相似。相比之下,日本PSC患者中CCA的发生率似乎较低。

相似文献

1
Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis.391例日本原发性硬化性胆管炎患者的预后及预后因素
Liver Int. 2008 Aug;28(7):983-9. doi: 10.1111/j.1478-3231.2008.01726.x. Epub 2008 Apr 7.
2
Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.273例原发性硬化性胆管炎患者的特征、结局及预后:一项单中心研究
Am J Gastroenterol. 2007 Jan;102(1):107-14. doi: 10.1111/j.1572-0241.2006.00872.x. Epub 2006 Oct 13.
3
Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group.原发性硬化性胆管炎:临床表现、自然病史及预后变量:一项意大利多中心研究。意大利原发性硬化性胆管炎研究组
Eur J Gastroenterol Hepatol. 1996 Jul;8(7):685-91.
4
Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.法国原发性硬化性胆管炎的特征和临床病程:一项前瞻性队列研究。
Eur J Gastroenterol Hepatol. 2010 Jul;22(7):842-7. doi: 10.1097/MEG.0b013e328331c2b7.
5
Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.原发性硬化性胆管炎患者肝胆癌的危险因素及临床表现:一项病例对照研究。
Hepatology. 1998 Feb;27(2):311-6. doi: 10.1002/hep.510270201.
6
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.原发性硬化性胆管炎中胆管癌的发病率及危险因素
Am J Gastroenterol. 2004 Mar;99(3):523-6. doi: 10.1111/j.1572-0241.2004.04067.x.
7
Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.原发性硬化性胆管炎终末期伴或不伴胆管癌的癌前胆管病变。
Am J Surg Pathol. 2010 Jan;34(1):27-34. doi: 10.1097/PAS.0b013e3181bc96f9.
8
High lifetime risk of cancer in primary sclerosing cholangitis.原发性硬化性胆管炎患者终生患癌风险高。
J Hepatol. 2009 Jan;50(1):158-64. doi: 10.1016/j.jhep.2008.08.013. Epub 2008 Oct 14.
9
Management of primary sclerosing cholangitis.原发性硬化性胆管炎的管理
Minerva Gastroenterol Dietol. 2009 Jun;55(2):163-72.
10
Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis.伴有和不伴有原发性硬化性胆管炎的年轻个体中的胆管癌。
Am J Gastroenterol. 2007 Aug;102(8):1677-82. doi: 10.1111/j.1572-0241.2007.01220.x. Epub 2007 Apr 13.

引用本文的文献

1
It's Not Always Infections When It Comes to Resource-Poor Countries: A Fascinating Case Report.在资源匮乏国家,情况并非总是感染问题:一则引人入胜的病例报告。
Cureus. 2024 Aug 8;16(8):e66469. doi: 10.7759/cureus.66469. eCollection 2024 Aug.
2
Challenges and Pitfalls in Pancreatobiliary Cytopathology.胆胰细胞学诊断的挑战与陷阱。
Acta Cytol. 2024;68(3):219-226. doi: 10.1159/000538687. Epub 2024 Apr 17.
3
ANXA1 is identified as a key gene associated with high risk and T cell infiltration in primary sclerosing cholangitis.膜联蛋白 A1 被鉴定为原发性硬化性胆管炎中与高风险和 T 细胞浸润相关的关键基因。
Hum Genomics. 2023 Sep 21;17(1):86. doi: 10.1186/s40246-023-00534-z.
4
Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.原发性硬化性胆管炎患者胆管癌的发病率及治疗结局综述。
World J Gastrointest Oncol. 2021 Oct 15;13(10):1336-1366. doi: 10.4251/wjgo.v13.i10.1336.
5
Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.通过胆汁中的甲基化标记物对原发性硬化性胆管炎患者胆管癌进行早期、准确的检测。
Hepatology. 2022 Jan;75(1):59-73. doi: 10.1002/hep.32125. Epub 2021 Dec 5.
6
Clinical Characterization of Ulcerative Colitis in Patients with Primary Sclerosing Cholangitis.原发性硬化性胆管炎患者溃疡性结肠炎的临床特征
Gastroenterol Res Pract. 2020 Nov 7;2020:7969628. doi: 10.1155/2020/7969628. eCollection 2020.
7
Geoepidemiologic variation in outcomes of primary sclerosing cholangitis.原发性硬化性胆管炎结局的地理流行病学差异
World J Hepatol. 2020 Apr 27;12(4):116-124. doi: 10.4254/wjh.v12.i4.116.
8
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review.原发性硬化性胆管炎(PSC)患者的胆管癌:全面综述。
Clin Rev Allergy Immunol. 2020 Feb;58(1):134-149. doi: 10.1007/s12016-019-08764-7.
9
Association between serum IgG level and clinical course in primary sclerosing cholangitis.原发性硬化性胆管炎患者血清 IgG 水平与临床病程的相关性。
BMC Gastroenterol. 2019 Aug 27;19(1):153. doi: 10.1186/s12876-019-1075-0.
10
Clinical guidelines for primary sclerosing cholangitis 2017.2017 年原发性硬化性胆管炎临床指南。
J Gastroenterol. 2018 Sep;53(9):1006-1034. doi: 10.1007/s00535-018-1484-9. Epub 2018 Jun 27.